Citius Oncology (CTOR) Q2 2025 earnings summary

Executive summary

• Transitioned from development-stage to commercial-stage after FDA approval of LYMPHIR for cutaneous T-cell lymphoma, focusing on U.S. launch and operational execution, with no revenue generated yet for the reported periods.

• Completed a merger and recapitalization in August 2024, resulting in a new corporate structure and increased outstanding shares.

• Operations are funded by Citius Pharma, with substantial doubt about the ability to continue as a going concern beyond May 2025 without additional capital.

• Engaged in discussions with commercial and strategic partners and seeking additional capital to support financial flexibility and commercial success.

Financial highlights

• Net loss for the three months ended March 31, 2025 was $7.7 million ($0.11 per share), up from $4.8 million ($0.07 per share) year-over-year; six-month net loss was $14.4 million compared to $9.6 million for the same period last year.

• R&D expenses rose to $3.1 million in Q2 2025 from $1.3 million in Q2 2024, mainly due to drug substance batch costs for pre-license inspection.

• G&A expenses increased to $2.2 million in Q2 2025 from $1.4 million in Q2 2024, driven by pre-commercial and commercial launch activities for LYMPHIR.

• Cash and cash equivalents were $112 as of March 31, 2025, with negative working capital of $31.7 million.

• No revenue was generated in either the current or prior year periods.

Outlook and guidance

• Funding from Citius Pharma is expected to last through May 2025; additional capital is required to continue operations and commercialize LYMPHIR.

• Actively seeking equity financing, strategic alternatives, and partnerships, with Jefferies LLC retained as exclusive financial advisor.

• Focused on disciplined capital deployment and operational execution to support LYMPHIR’s U.S. launch.

• Uncertainty remains regarding the ability to raise sufficient funds or generate substantial revenue from LYMPHIR sales.